Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

Anti-PD-L1 antibodies inhibit interactions between PD-L1 and PD-1 and interactions between PD-L1 and B7-1, thereby reinvigorating anticancer immunity. Although there are numerous ongoing clinical studies evaluating combinations of standard chemotherapies and anti-PD-L1 antibodies, irinotecan has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwai, Toshiki, Sugimoto, Masamichi, Wakita, Daiko, Yorozu, Keigo, Kurasawa, Mitsue, Yamamoto, Kaname
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101148/
https://www.ncbi.nlm.nih.gov/pubmed/30140379
http://dx.doi.org/10.18632/oncotarget.25830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101148/
https://www.ncbi.nlm.nih.gov/pubmed/30140379
http://dx.doi.org/10.18632/oncotarget.25830

Ejemplares similares